GlobeNewsWire
27 Aug 2026, 00:32 UTC · 12w ago
Mesoblast Reports Substantial Revenue Growth to US$120M
Impact · against what's priced in
Mesoblast's financial performance and pipeline progress provide significant catalysts, particularly the completion of the Phase 3 trial for chronic low back pain and the planned expansion of RYONCIL into the larger adult market. These developments offer a clear path toward multi-billion-dollar revenue opportunities and reduced funding risk.
- MSB+0.70
No priced-in read yet
- In context
The completion of patient treatment in the Phase 3 trial for chronic low back pain and the expansion of RYONCIL into an adult market three times larger than the pediatric one create substantial new growth catalysts. Additionally, reporting US$120M in revenue and US$104M in gross profit significantly strengthens the company's cash position.





